Brief CBT for Anxiety and Advanced Cancer
OBJECTIVES:
- To develop and examine the feasibility and patient acceptability of administering a
manualized cognitive-behavioral intervention that improves quality of life by treating
anxiety in patients with advanced cancer.
- To estimate the effect size of a manualized cognitive-behavioral intervention to reduce
anxiety in patients with advanced cancer.
- To estimate the effect size for the secondary outcomes (i.e., depression and quality of
life) and to examine the extent to which specific variables (i.e., sex, age,
chemotherapy side effects, pain levels) are consistent with the conceptual model as
potential moderators of treatment effect.
OUTLINE: This is a pilot study followed by a randomized study. Patients are stratified
according to type of cancer.
- Pilot study: Patients complete qualitative interviews to explore ways that anxiety
impacts patients, to identify components of a cognitive-behavioral therapy intervention
that are most useful, and to determine the optimal method of delivery for the
intervention (e.g., number and timing of interventions, administration during
chemotherapy infusions when feasible). Based upon these results a full treatment manual
is written for use in the randomized study.
Patients are then randomized to 1 of 2 treatment arms.
- Arm I (cognitive-behavioral therapy): Patients undergo six-seven 90-minute treatment
sessions (over 2 months) based on the results of the pilot study. Modules include
psychoeducation and goal setting; relaxation training; cognitive restructuring; coping
with cancer fears; activity planning and pacing; and review, termination, and plan for
continued use of skills.
- Arm II (routine care): Patients receive routine medical care.
At the completion of treatment, all participants meet with a blinded independent assessor to
assess outcomes. Patients undergo psychiatric evaluation, including the Hamilton Anxiety
Rating Scale (HAM-A), the Montgomery Asberg Depression Rating Scale (MADRS), the Mini
International Neuropsychiatric Interview (MINI), and a psychosocial self-reported battery at
baseline and after 2-3 months.
After completing treatment, patients who underwent routine care (arm II) may undergo
cognitive-behavioral therapy as in arm I, if desired.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Anxiety symptoms as measured by the Hamilton Anxiety Rating Scale
The Hamilton Anxiety Ratings Scale (HAM-A) consists of 14 items that provide an overall measure of global anxiety.
1) At enrollment pre-intervention. 2) Post intervention (2-3 months after enrollment)
No
Joseph Greer, PhD
Principal Investigator
Massachusetts General Hospital
United States: Partners Human Research Committee
CDR0000597438
NCT00706290
April 2007
August 2010
Name | Location |
---|---|
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |